VBI Vaccines Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor VBI Vaccines te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat VBI Vaccines onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:VBIV.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2024	9	-84	-51	-51	N/A
12/31/2023	9	-94	-62	-61	N/A
9/30/2023	8	-115	-70	-68	N/A
6/30/2023	2	-119	-81	-77	N/A
3/31/2023	1	-120	-80	-75	N/A
12/31/2022	1	-113	-78	-74	N/A
9/30/2022	1	-111	-77	-73	N/A
6/30/2022	1	-102	-63	-60	N/A
3/31/2022	0	-73	-55	-53	N/A
12/31/2021	1	-70	-42	-40	N/A
9/30/2021	1	-66	-40	-38	N/A
6/30/2021	1	-63	-51	-49	N/A
3/31/2021	1	-56	-47	-46	N/A
12/31/2020	1	-46	-48	-47	N/A
9/30/2020	1	-42	-40	-39	N/A
6/30/2020	2	-45	-39	-38	N/A
3/31/2020	2	-49	-44	-42	N/A
12/31/2019	2	-55	-52	-49	N/A
9/30/2019	4	-63	-54	-48	N/A
6/30/2019	4	-62	-54	-47	N/A
3/31/2019	4	-66	-58	-51	N/A
12/31/2018	3	-64	-52	-46	N/A
9/30/2018	1	-56	-51	-47	N/A
6/30/2018	1	-50	-42	-40	N/A
3/31/2018	1	-43	-33	-32	N/A
12/31/2017	1	-39	N/A	-31	N/A
9/30/2017	1	-36	N/A	-30	N/A
6/30/2017	1	-33	N/A	-28	N/A
3/31/2017	1	-31	N/A	-25	N/A
12/31/2016	1	-23	N/A	-19	N/A
9/30/2016	0	-19	N/A	-14	N/A
6/30/2016	0	-31	N/A	-14	N/A
3/31/2016	1	-25	N/A	-9	N/A
12/31/2015	1	-26	N/A	-9	N/A
9/30/2015	2	-23	N/A	-8	N/A
6/30/2015	2	-6	N/A	-7	N/A
3/31/2015	2	-6	N/A	-5	N/A
12/31/2014	3	-6	N/A	-5	N/A
12/31/2013	2	-9	N/A	-5	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van VBIV.Q boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van VBIV.Q naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van VBIV.Q naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van VBIV.Q naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van VBIV.Q naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van VBIV.Q naar verwachting over 3 jaar hoog zal zijn

VBI Vaccines Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates increase by 291%, EPS downgraded

Consensus EPS estimates upgraded to US$4.46 loss

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

Consensus EPS estimates fall by 1,377%

No longer forecast to breakeven

Recent updates

VBI Vaccines Inc. Issues Voluntary Nationwide Recall of All PreHevbrio Vaccine Due to Discontinuation of Company Operations

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

VBI Vaccines Inc. Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

VBI Vaccines Inc. Announces PreHevbrio Availability in the United States for the Prevention of Hepatitis B in Adults

Forecast to breakeven in 2024

Consensus revenue estimates fall by 49%

Consensus revenue estimates fall by 49%

No longer forecast to breakeven

Price target decreased to US$6.67